NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
Clinical Trials
9 trialsNCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03358875 2025-02-10
RATIONALE-303
BeiGene
Phase 3 Completed
NCT03663205 2025-02-04
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03924986 2025-01-31
RATIONALE-309
BeiGene
Phase 3 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03594747 2024-10-26
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
BeiGene
Phase 3 Completed